Novel targeted therapies for NSCLC: Exploring HER2 dysregulation episode artwork

EPISODE · Oct 26, 2021 · 33 MIN

Novel targeted therapies for NSCLC: Exploring HER2 dysregulation

from touchPODCAST · host touchpodcast

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC. The experts Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/

Episode metadata supplied by the publisher feed · Published Oct 26, 2021

Embed this episode

Ready to play

Novel targeted therapies for NSCLC: Exploring HER2 dysregulation

0:00 33:13

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 33 minutes long.

When was this touchPODCAST episode published?

This episode was published on October 26, 2021.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!